BridgeBio Pharma (BBIO) Cash from Investing Activities (2018 - 2026)

BridgeBio Pharma has disclosed Cash from Investing Activities across 9 years of filings, most recently posting -$42.7 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$42.7 million, down 2579.31% year-over-year; the trailing twelve-month figure through Mar 2026 was -$65.6 million (down 280.13% YoY), and the FY2025 annual result was -$24.5 million, down 140.29% from the prior year.
• Cash from Investing Activities came in at -$42.7 million for Q1 2026 at BridgeBio Pharma, down from -$14.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $149.7 million in Q2 2022 to a low of -$42.7 million in Q1 2026.
• The 5-year median for Cash from Investing Activities is $4.5 million (2025), against an average of $29.5 million.
• Across the five-year window, Cash from Investing Activities soared 32586.03% in 2022 and slumped 4804.55% in 2024, its largest moves.
• BridgeBio Pharma's Cash from Investing Activities stood at $18.0 million in 2022, then tumbled by 100.37% to -$66000.0 in 2023, then plunged by 4804.55% to -$3.2 million in 2024, then plunged by 343.44% to -$14.4 million in 2025, then tumbled by 197.72% to -$42.7 million in 2026.
• The last three Cash from Investing Activities figures came in at -$42.7 million (Q1 2026), -$14.4 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.